| Heading: |
Neuroendocrine Cancer: Radiotherapy |
| Question ID: |
1787466 |
| UIN: |
HL6052 |
| House: |
Lords |
| Date tabled: |
2025-03-24 |
| Asking Member ID: |
4301 |
| Asking Member display name: |
Baroness Hodgson of Abinger
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Baroness Hodgson of Abinger
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what plans they have to increase funding for minimally invasive cancer therapies, in particular selective internal radiation therapy for neuroendocrine tumours that have spread to the liver. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-02 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Radiotherapy treatment for cancer is highly individualised and decisions about cancer treatment are typically made by clinicians and multidisciplinary teams of healthcare professionals. They consider all aspects of a patient's health and circumstances whe... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |